Colchicine

Microtubule inhibitor / anti-inflammatory

Response rate
12.5% complete response
Onset
Weeks
Route
Oral 0.5–1mg daily
Line
Alternative
IgM effect
N/A

Evidence summary

AIDA Network real-life data shows colchicine monotherapy achieves complete response in only 12.5% of TRAPS patients, with partial response in 58% and no response in 29%. May be considered for patients with low-penetrance variants (INSAID Group B/C) and mild phenotypes where biologic therapy seems excessive.

Sources (2)

DetailsRigante D et al. (2020) Role of colchicine treatment in tumor necrosis factor receptor associated periodic syndrome (TRAPS): real-life data from the AIDA Network · Mediators InflammDOI ↗
DetailsPapa R et al. (2021) INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever Registry · J Allergy Clin Immunol PractDOI ↗